The potential of polygenic scores to improve cost and efficiency of clinical trials

Akl C Fahed; Anthony A Philippakis; Amit V Khera

doi:10.1038/s41467-022-30675-z

The potential of polygenic scores to improve cost and efficiency of clinical trials

Nat Commun. 2022 May 25;13(1):2922. doi: 10.1038/s41467-022-30675-z.

Authors

Akl C Fahed^{1

2

3}, Anthony A Philippakis^{4

5}, Amit V Khera^{6

7

8

9}

Affiliations

¹ Division of Cardiology and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
² Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
³ Department of Medicine, Harvard Medical School, Boston, MA, USA.
⁴ Data Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
⁵ Eric and Wendy Schmidt Center, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
⁶ Division of Cardiology and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. avkhera@mgh.harvard.edu.
⁷ Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. avkhera@mgh.harvard.edu.
⁸ Department of Medicine, Harvard Medical School, Boston, MA, USA. avkhera@mgh.harvard.edu.
⁹ Verve Therapeutics, Cambridge, MA, USA. avkhera@mgh.harvard.edu.

Abstract

Polygenic scores can identify individuals with high disease risk based on inborn DNA variation. We explore their potential to enrich clinical trials by identifying individuals based on higher risk of disease (‘prognostic enrichment’), or increased probability of benefit (‘predictive enrichment’).

The potential of polygenic scores to improve cost and efficiency of clinical trials

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding